Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03670810 · ClinicalTrials.gov registry record · Phase 3
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
A Phase 3 study of Migraine, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,633
- Enrollment target
- 20
- Study locations
NCT03670810 is a Phase 3 study of Migraine that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,633 participants, above the 342-participant average among 102 other Migraine trials with a reported enrollment target (377% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT03670810, a Phase 3 study of Migraine, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,633 participants
- Enrollment target
- 20
- Study locations
Study Summary
The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lasmiditan
Study Locations (20)
New York
- Dent Neurological Institute - Amherst
- Island Neuro Associates,PC - Plainview
- Montefiore Headache Center - The Bronx
Other
- Christian-Doppler-Klinik - Salzburg
- AKH - Vienna
- Algemeen Ziekenhuis St Jan Brugge - Bruges
District of Columbia
- Georgetown University Hospital - Washington D.C.
- George Washington University Medical Center - Washington D.C.
Alabama
- Rehabilitation & Neurological Services LLC - Huntsville
Arizona
- Barrow Neurological Institute - Phoenix
California
- UCSD Altman Clinical & Translational Research Institute (ACTRI) - La Jolla
Colorado
- Colorado Neurological Institute - Englewood
Illinois
- Diamond Headache Clinic - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,633 participants |
| Start Date | 2019-06-24 |
| Est. Completion | 2021-07-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03670810
The ClinicalTrials.gov registry entry for NCT03670810 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,633 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 342-participant average among 102 other Migraine trials with a reported enrollment target (377% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03670810 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, Other, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03670810 about?
NCT03670810 is a clinical study titled "A Study of Lasmiditan (LY573144) Over Four Migraine Attacks". The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.
What is the current status of trial NCT03670810?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,633 participants. The study started on 2019-06-24. Estimated completion is 2021-07-08.
What conditions does trial NCT03670810 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT03670810?
The interventions under investigation include: Placebo (DRUG), Lasmiditan (DRUG).
Who is sponsoring clinical trial NCT03670810?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03670810 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.